Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab

Leuk Lymphoma. 2023 Dec;64(14):2351-2353. doi: 10.1080/10428194.2023.2262641. Epub 2023 Dec 25.

Authors

Robert Stuver¹, Santosha A Vardhana¹, Akshay Bedmutha², Karmela Kim Chan³, Rosna Mirtcheva-Trocheva², Anton Nosov², Heiko Schöder², Alison Moskowitz¹

Affiliations

¹ Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Hospital for Special Surgery, New York, NY, USA.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Hodgkin Disease* / diagnosis
Hodgkin Disease* / drug therapy
Humans
Lymphoma, Non-Hodgkin* / pathology
Methotrexate / adverse effects

Substances

Methotrexate
pembrolizumab
Antibodies, Monoclonal, Humanized

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States